Business Context and Reporting Period
This Form 8-K Current Report was filed by Longeveron Inc. on October 1, 2021. The Company is a Delaware corporation and an emerging growth company, with its Class A Common Stock (LGVN) trading on The Nasdaq Capital Market. The report primarily addresses Regulation FD disclosures regarding a company presentation and press release, as well as the disclosure of a securities class action lawsuit.
Key Financial Metrics
This filing is a current report regarding specific events and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Events
- Regulation FD Disclosure (Item 7.01): On October 1, 2021, the Company made an updated presentation available on its website. Additionally, on September 29, 2021, the Company issued a press release announcing potential biomarker data correlating with the bioactivity of its product candidate, Lomecel-B, which was presented at the International Conference for Frailty & Sarcopenia Research.
- Legal Proceedings (Item 8.01): On September 13, 2021, the Company and certain directors and officers were named as defendants in a purported securities class action lawsuit filed in the U.S. District Court for the Southern District of Florida. The suit alleges material misstatements in the Company's initial public offering materials and seeks damages for purchasers of common stock between February 12, 2021, and August 12, 2021.
Guidance, Outlook, and Risks
Management Commentary: The Company stated that the allegations in the class action lawsuit are without merit and intends to vigorously defend against them. The Company also noted it does not intend to file further 8-K reports regarding additional lawsuits based on substantially similar allegations.
Risks and Contingencies: The primary risk disclosed is the ongoing securities class action litigation. The filing explicitly states that the information in the attached presentation and press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.2) regarding the Lomecel-B biomarker data to understand the scientific context and limitations.
- Examine the updated Company presentation (Exhibit 99.1) for any forward-looking statements or strategic updates.
- Monitor the status of the securities class action lawsuit filed in the Southern District of Florida for potential impacts on the Company's operations or capital.
- Verify the Company's most recent financial position in its latest 10-K or 10-Q filings, as this 8-K contains no financial data.